What Is Hexarelin? Benefits, Research & Safety
A potent growth hormone-releasing peptide with notable cardioprotective properties independent of GH release.
UK summary: Not a licensed UK medicine. Potent GHRP with research interest in cardioprotection. Prohibited at all times under WADA S2. Sometimes cited for tachyphylaxis (reduced effect with chronic use) more than other GHRPs.
Quick Facts
Overview
Hexarelin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Potent GHRP with research interest in cardioprotection. Prohibited at all times under WADA S2. Sometimes cited for tachyphylaxis (reduced effect with chronic use) more than other GHRPs.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for therapeutic use.
- Notes: Hexarelin is not approved by any regulatory authority. It is prohibited in sports by WADA. Available only as a research compound.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Most potent GHRP for biggest GH spike.
- Cardioprotective for athletes during heavy training.
- Safe long-term for body composition.
- Cleaner cortisol profile than GHRP-6.
07Common internet claims
- Marketed in bodybuilding and 'anti-ageing' stacks.
- Sold online as the most potent GHRP.
- Promoted for cardioprotection extrapolated from animal data.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cardioprotective for athletes / strength trainers” | D | No | High | Animal-model and ex-vivo cardiac data exist; human cardioprotection claims are not established. |
| “Most potent GHRP — biggest GH spike” | C | Limited | High | Short-term studies show high GH-release potency; potency is not the same as clinical benefit. |
| “Use long-term for body composition” | E | No | High | Long-term safety in healthy adults is not established; chronic GHRP use raises tachyphylaxis and cortisol concerns. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Tachyphylaxis (diminishing effect) with chronic use.
- Cortisol and prolactin elevation.
- Water retention, joint pain, carpal tunnel symptoms.
- Theoretical oncologic risk from sustained IGF-1 elevation.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. Research compound only.
14EU legal position
Not approved for therapeutic use.
15What this page cannot tell you
- Whether a UK-purchased vial contains Hexarelin at the labelled concentration.
- Whether cardioprotective effects in animal studies translate to humans.
- What chronic use does to natural ghrelin signalling and hunger regulation.
- WADA detection windows — assume positive on test, strict-liability.
16Last reviewed
17Citation quality score
18Research gaps
- Cardiac outcome trials in humans absent.
- Phase 3 trials for any indication absent.
- Long-term safety unstudied.
- Combination-stack safety with CJC-1295, MK-677 uncharacterised.
19Safer alternatives / established care pathways
- Endocrinologist review for adult GH-deficiency with formal testing.
- Cardiac risk assessment and standard NHS cardioprotective interventions (statins, BP control, exercise).
- Licensed recombinant HGH under specialist supervision where confirmed deficiency.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Hexarelin a licensed UK medicine?
- What is the WADA position?
- What licensed alternatives exist for the underlying issue I'm asking about?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent growth hormone release (among the strongest GHRPs)
- 2Cardioprotective effects in research models
- 3Protection against ischemia-reperfusion injury
- 4Elevated IGF-1 levels
- 5Potential benefits for cardiac function
Claim vs Evidence
How popular claims about Hexarelin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cardioprotective for athletes / strength trainers” | D | No | High | Animal-model and ex-vivo cardiac data exist; human cardioprotection claims are not established. |
| “Most potent GHRP — biggest GH spike” | C | Limited | High | Short-term studies show high GH-release potency; potency is not the same as clinical benefit. |
| “Use long-term for body composition” | E | No | High | Long-term safety in healthy adults is not established; chronic GHRP use raises tachyphylaxis and cortisol concerns. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 100-200 mcg per dose |
| Frequency | 2-3 times daily (note: desensitisation may occur) |
| Duration | Often used in shorter cycles due to desensitisation |
| Notes | Hexarelin is not approved for therapeutic use. Desensitisation with repeated use may limit long-term effectiveness. Cycling or intermittent use may be considered. Any use should be under medical supervision. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection
- Intravenous (research settings)
| Half-Life | Stability |
|---|---|
| Approximately 70 minutes (longer than some other GHRPs) | Lyophilised powder stable when properly stored |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Flushing
- Water retention
- Tingling or numbness
- Injection site reactions
- Cortisol elevation
Rare Risks & Concerns
- Desensitisation with chronic use
- Unknown long-term effects
- Effects on other hormonal axes
- Theoretical concerns with tumour growth
Contraindications
- Active malignancy
- Pregnancy and breastfeeding
- Unstable cardiac conditions
- Diabetes (monitor closely)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
Clinical Studies Summary
Cardioprotective Effects of Hexarelin
Research demonstrating Hexarelin's ability to protect cardiac tissue from ischemic injury.
Looking for Hexarelin?
Source research-grade Hexarelin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Hexarelin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Hexarelin a licensed UK medicine?
- What is the WADA position?
- What licensed alternatives exist for the underlying issue I'm asking about?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
CJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-2
A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.
Learn moreGHRP-6
The first clinically evaluated growth hormone-releasing peptide, notable for its potent GH release and pronounced appetite-stimulating effects.
Learn more